Showing papers for search query "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"

     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Dissolution testing for generic drugs: an FDA perspective
     Author ['OM Anand', 'XY Lawrence', 'DP Conner', 'BM Davit']
     Venue The AAPS journal
     Year 2011
     Abstract In vitro dissolution testing is an important tool used for development and approval of generic dosage forms. The objective of this article is to summarize how dissolution testing is used for the approval of safe and effective generic drug products in the United States (US)
     Url https://link.springer.com/article/10.1208/s12248-011-9272-y


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
     Author ['F Dieterle', 'F Sistare', 'F Goodsaid', 'M Papaluca']
     Venue Nature …
     Year 2010
     Abstract The first formal qualification of safety biomarkers for regulatory decision making marks a milestone in the application of biomarkers to drug development. Following submission of drug toxicity studies and analyses of biomarker performance to the Food and Drug
     Url https://www.nature.com/articles/nbt.1625?message-global=remove&page=7


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs
     Author ['EH Morrato', 'B Druss', 'DM Hartung']
     Venue Archives of general …
     Year 2010
     Abstract Context In 2003, the Food and Drug Administration (FDA) required a warning on diabetes risk for second-generation antipsychotic (SGA) drugs. The American Diabetes Association (ADA) and American Psychiatric Association (APA) recommended glucose and lipid testing
     Url https://jamanetwork.com/journals/jamapsychiatry/article-abstract/210512


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Banning a risky product cannot improve any consumer's welfare (properly understood), with applications to FDA testing requirements
     Author ['R Higgs']
     Venue The Review of Austrian Economics
     Year 1994
     Abstract Conclusion Banning a product can never improve the well-being of consumers properly understood, that is, understood as individual consumers' prospective and subjective utility. This proposition remains valid even when risk is incorporated into the analysis. Risk of
     Url https://link.springer.com/content/pdf/10.1007/BF01101940.pdf


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing
     Author ['LD Fisher']
     Venue Controlled clinical trials
     Year 1999
     Abstract Carvedilol (Coreg®), a beta-and alpha-blocker and an antioxidant drug, was evaluated for moderate to severe heart failure patients in a program containing four United States and one Australia/New Zealand study. The data were evaluated twice by the Cardiovascular and
     Url https://www.sciencedirect.com/science/article/pii/S0197245698000543


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape
     Author ['N Ravi', 'DL Cortade', 'E Ng', 'SX Wang']
     Venue Biosensors and Bioelectronics
     Year 2020
     Abstract The rapidly spreading outbreak of COVID-19 disease is caused by the SARS-CoV-2 virus, first reported in December 2019 in Wuhan, China. As of June 17, 2020, this virus has infected over 8.2 million people but ranges in symptom severity, making it difficult to assess
     Url https://www.sciencedirect.com/science/article/pii/S0956566320304486


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product
     Author ['SA Qureshi', 'IJ McGilveray']
     Venue European journal of pharmaceutical sciences
     Year 1999
     Abstract To evaluate variability in drug dissolution testing 28 laboratories analyzed USP calibrators, US FDA prednisone tablets and a marketed glibenclamide tablet product. The experiments were conducted using paddle and basket methods at 50 (calibrators) and 75
     Url https://www.sciencedirect.com/science/article/pii/S0928098798000347


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title FDA regulation of stem cell–based products
     Author ['DW Fink']
     Venue Science
     Year 2009
     Abstract undifferentiated ES cells demonstrated by spontaneous formation of teratoma-like masses composed of differentiated cells from the three somatic germ layers after injection in adult, immunodeficient mice (3, 4) requires the attention of preclinical testing. FDA review experience
     Url https://science.sciencemag.org/content/324/5935/1662.abstract


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi
     Author ['JD Planer', 'MA Hulverson', 'JA Arif', 'RM Ranade']
     Venue PLoS Negl Trop …
     Year 2014
     Abstract An estimated 8 million persons, mainly in Latin America, are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease. Existing antiparasitic drugs for Chagas disease have significant toxicities and suboptimal effectiveness, hence new therapeutic strategies
     Url https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002977


     Search term "Software+Validation"+OR+"Software+Verification"+OR+"Testing"+"FDA"
     Title Commercialization of genetic testing services: the FDA, market forces, and biological tarot cards
     Author ['MJ Malinowski', 'RJR Blatt']
     Venue Tul. L. Rev.
     Year 1996
     Abstract OncorMed, Inc.(OncorMed), a small Gaithersburg, Maryland, biotechnology company involved in general cancer testing, announced in January 1996 that it had begun selling a testing service'to identify 1. We employ definitions pertaining to genetic testing adopted by
     Url https://heinonline.org/hol-cgi-bin/get_pdf.cgi?handle=hein.journals/tulr71&section=34

